quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·139d
PRRelease
INmune Bio Inc. logo

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

INMB· INmune Bio Inc.
Health Care
Original source

Companies

  • INMB
    INmune Bio Inc.
    Health Care

Recent analyst ratings

  • Jul 1UpdateScotiabank$0.60
  • Jul 1UpdateBTIG Research-
  • Jan 28UpdateRodman & Renshaw$23.00
  • Oct 21UpdateAlliance Global Partners$20.00
  • Sep 27UpdateRaymond James$18.00
  • Aug 22UpdateScotiabank$22.00

Related

  • SEC10h
    SEC Form DEF 14A filed by INmune Bio Inc.
  • PR7d
    INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
  • SEC24d
    SEC Form 10-K filed by INmune Bio Inc.
  • PR24d
    INmune Bio Inc. Announces 2025 Results and Provides Business Update
  • PR30d
    INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
  • PR35d
    INmune Bio's MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer's Disease
  • SEC55d
    INmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC59d
    INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022